Irritable bowel syndrome: The present view of the problem


The paper gives an update on irritable bowel syndrome and reveals problems in its classification, pathogenesis, clinical picture, and differential diagnosis. It presents principles in the treatment of patients in the context of evidence-based medicine and proposes a treatment algorithm for the major types of irritable bowel syndrome.

Full Text

Синдром раздраженного кишечника. Современный взгляд на проблему. - Аннотация. В статье изложены современные данные о синдроме раздраженного кишечника, раскрыты вопросы классификации, патогенеза, особенности клинической картины и дифференциальной диагностики. Представлены принципы лечения больных с позиций доказательной медицины, предложен алгоритм лечения при основных вариантах синдрома раздраженного кишечника.


  1. Drossman D.A. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology 2006; 130 (5): 1377-1390.
  2. Маев И.В., Черемушкин С.В., Лебедева Е.Г. Синдром раздраженного кишечника. Рос журн гастроэнтерол, гепатол, колопроктол 2000; 5: 70.
  3. Ros E., Zambon D. Postcholecystectomy symptoms. A prospective study of gallstone patients before and two years after surgery. Gut 1987; 28: 1500-1504.
  4. Burns D.G. The risk of abdominal surgery in irritable bowel syndrome. S Afr Med J 1986; 70: 91.
  5. Walker E.A., Gelfand A.N., Gelfand A.N. et al. Chronic pelvic pain and gynecological symptoms in women with irritable bowel syndrome. J Psychosom Obstet Gynaecol 1996; 17 (1): 39-46.
  6. Ивашкин В.Т., Драпкина О.М., Полуэктова Е.А. Болезни органов пищеварения. Синдромом раздраженного кишечника. Метод. рекоменд. 2008. Доступно на
  7. Маев И.В., Черемушкин С.В. Синдром раздраженного кишечника: учеб. пос. М 2012.
  8. Ohman L., Simren M. Pathogenesis of IBS: role of inf lammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-173.
  9. Успенский Ю.П., Захаренко С.М., Фоминых Ю.А. Инфекционные агенты и синдром раздраженного кишечника. Тер арх 2011; 2: 64-67.
  10. Парфенов А. И., Ручкина И. Н., Атауллаханов Р. И. и др. Постинфекционный синдром раздраженного кишечника. Тер арх 2009; 2: 39-45.
  11. Piche T., Saint-Paul M.C., Dainese R. et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57: 468-473.
  12. Walker M.M., Talley N.J., Prabhakar M. et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29: 765-773.
  13. Barbara G., Stanghellini V., De Giorgio R. et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
  14. Guilarte M., Santos J., de Torres I. et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-209.
  15. Lee K.J., Kim Y.B., Kim J.H. et al. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008; 23: 1689-1694.
  16. Barbara G., Wang B., Stanghellini V. et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37.
  17. Corinaldesi R., Stanghellini V., Cremon C. et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30: 245-252.
  18. World Gastroenterology Organization. Global Guideline. Irritable bowel syndrome: a global perspective. 2009.
  19. Chang L., Ameen V.Z., Dukes G.E. et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005; 100: 115-123.
  20. Krause R., Ameen V., Gordon S.H. et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007; 102: 1709-1719.
  21. Nicandro J.P.A., Shin P., Shringarpure R. et al. Alosetron is associated with improvements in treatment satisfaction and quality of life [abstract M1058]. Presented at the Digestive Disease Week 2010; May 1-5, 2010; New Orleans, LA.
  22. Ford A.C., Talley N.J., Schoenfeld P.S. et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-378.
  23. Talley N.J., Kellow J.E., Boyce P. et al. Anti-depressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci 2008; 53: 108-115.
  24. Kuiken S.D., Tytgat G.N., Boeckxstaens G.E. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 219-228.
  25. Masand P.S., Pae C.U., Krulewicz S. et al. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics 2009; 50: 78-86.
  26. Tack J., Broekaert D., Fischler B. et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55: 1095-1103.
  27. Lotronex (alosetron hydrochloride) tablets [package insert]. San Diego, CA: Prometheus Laboratories Inc; 2010.



Abstract - 98


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2020 Maev I.V., Cheremushkin S.V., Sutugina E.A., Cheremushkina N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies